GlassScriptPhysician profile
Jessica Pedersen
NPI 1992144687
$2,776.12
in general payments reported to CMS, 2019-2025
22 companies · $579 in 2025
The $579 reported for 2025 was more than what 95% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $274 · 2020: $37.07 · 2021: $260 · 2022: $419 · 2023: $581 · 2024: $627 · 2025: $579.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,787.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,786.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $669.69 | 2021-2025 | Qelbree, Qelbree |
| Tris Pharma INC | $413.22 | 2019-2025 | Dyanavel Xr, Onyda Xr |
| Corium, LLC | $304.01 | 2022-2025 | Azstarys |
| Pfizer INC. | $299.79 | 2019-2025 | |
| Ironshore Pharmaceuticals INC. | $135.82 | 2019-2024 | Jornay Pm |
| Takeda Pharmaceuticals U.S.A., INC. | $134.50 | 2021-2024 | Elaprase |
| Seqirus USA INC | $132.68 | 2021-2025 | Flucelvax, Flucelvax Quadrivalent |
| Neos Therapeutics, LP | $122.50 | 2019-2024 | Cotempla Xr-Odt |
| Merck Sharp & Dohme LLC | $106.76 | 2021-2025 | Vaxneuvance, Gardasil 9, Vaxelis |
| Sanofi Pasteur INC. | $81.78 | 2022-2025 | |
| Cranial Technologies, INC | $53.03 | 2024-2025 | Doc Band |
| Sobi, INC | $49.50 | 2022-2024 | |
| Glaxosmithkline, LLC. | $46.33 | 2020-2025 | Bexsero |
| Teva Pharmaceuticals USA, INC. | $40.95 | 2019-2023 | Airduo Digihaler |
| Novartis Pharmaceuticals Corporation | $38.21 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertical Pharmaceuticals, LLC | $30.66 | 2019 | |
| Jazz Pharmaceuticals INC. | $28.93 | 2025 | |
| Cognoa, INC. | $22.50 | 2021 | |
| Ars Pharmaceuticals Operations, INC. | $19.15 | 2025 | Neffy |
| Aytu Biopharma, INC. | $17.52 | 2024 | Karbinal |
| Sanofi-Aventis U.S. LLC | $16.69 | 2024 | |
| Kaleo, INC. | $11.90 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jessica Pedersen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.